Today let’s look into Immuno-oncology (I/O)- particularly using PD1/PDL1 as a case study!

With several companies turning to I/O and immuno-therapy for cancer therapeutics, we offer several upstream and downstream targets of interest for patient stratification! One frequent question from our clients is that: “It’s a cool technology, but how can it benefit my PD-1/PD-L1 research, as such biomarkers don’t have much downstream activity?”

Knowing the baseline activation level of these biomarkers is crucial for patient recruitment and therapeutic decision-making. PD1-based therapies would not generate many outcomes if patients have too weak of a baseline activity to elicit any clinical difference. Additionally, the activation of compensatory pathways is often the culprit for treatment resistance. In the case of PD1, normal levels of PD1 activities require functional STAT/IFN activities from upstream, both of which also interact with many other immune checkpoint markers. Knowing the activity levels of the entire signaling network can be essential in determining companion diagnostics or combination therapies.

With 700+ and growing validated analytes and detection of up to 500X dynamic range, Theralink Technologies’ Next Generation Proteomics (NGP)TM platform can be a remarkable tool to advance oncology and precision medicine. To explore some more of our I/O pathways visit our biopharma page or drop us a line in the contact form for more customizable options!

Pathway Created with BioRender

#drugdiscovery #cancerresearch #cancercells #translationalmedicine #translationalresearch #science #medicine #healthcare #biotechnology #precisionmedicine #precisiononcology #proteomics #biomarker #biopharma #biopharmaceuticals #healthtech #biotech